Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Halobetasol Propionate And Tazarotene · Duobrii

Small molecule · Agonist of retinoic acid receptor alpha (RARA), retinoic acid receptor beta (RARB) and retinoic acid receptor gamma (RARG) · developed by Bausch

Approved FDA, Apr 2019

BHC Developer

1 Registered trials

What is Halobetasol Propionate And Tazarotene?

Duobrii is a topical combination of halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug converted to tazarotenic acid. Tazarotenic acid binds retinoic acid receptors (RARα, RARβ, RARγ) with selectivity for RARβ and RARγ, modifying gene expression.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Duobrii
Drug type: Small molecule
Targets: retinoic acid receptor alpha (RARA), retinoic acid receptor beta (RARB), retinoic acid receptor gamma (RARG)
Mechanism: Agonist of retinoic acid receptor alpha (RARA), retinoic acid receptor beta (RARB) and retinoic acid receptor gamma (RARG)
Pathways: gene_expression
Therapy area: Dermatology
Developer: Bausch (BHC)
FDA status: Approved as Duobrii (April 25, 2019), NDA209354 · FDA label

✅ FDA-approved uses

Plaque psoriasis

From the indications section of the FDA label (version of Jan 1, 2020). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05608499	Phase 3	Acne Keloidalis Nuchae	Terminated	BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acne Keloidalis NuchaeAKN

Other drugs acting on RARA / RARB / RARG

IDP-118 FDA approved

More from Bausch

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Bupropion FDA approved IDP-118 FDA approved IDP-126 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Rifaximin FDA approved Timolol FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind Halobetasol Propionate And Tazarotene

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z